公司資料
Editas Medicine 股價、新聞與催化劑
- 股票代碼:
- EDIT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.84 USD (+0.71%)
收盤價
最後更新: 2026年8月17日
433M USD
市值
股價為何變動
As of Aug 17, 2026, EDIT closed up 0.71% at $2.84. No new same-company headline was identified in the current news window.
公司概覽
In Vivo CRISPR Medicines
Editas Medicine is developing in vivo CRISPR gene-editing therapies intended to produce durable therapeutic effects after a single administration. Following the discontinuation of its earlier reni-cel program, the company’s near-term strategy is concentrated on cardiometabolic editing.
EDIT-401
EDIT-401 is designed to upregulate LDL receptor protein in the liver and thereby lower LDL cholesterol. Preclinical studies showed large mean LDL-C reductions and also demonstrated reductions in apolipoprotein B and lipoprotein(a), supporting its development as a one-time treatment for hyperlipidemia.
Initial HeFH Development
The first clinical indication is heterozygous familial hypercholesterolemia, an inherited disorder that produces elevated LDL-C and early cardiovascular risk. Editas plans to use the initial trial to establish safety, dose response and human proof of concept before considering broader hyperlipidemia populations.
未來催化劑
- Initiation of the first-in-human EDIT-401 trial in 2026.
- Early human proof-of-concept data for EDIT-401 expected by year-end 2026.
- Completion of dose-finding enrollment and topline EDIT-401 results expected in 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。